Delisting riskPopularity #4,340
iSpecimen (ISPC)
Order-driven marketplace for annotated human biospecimens.
$1.26
After hours−0.00 (−0.31%)
At close$1.27(−4.17%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3 | 3 | 2 | 3 | 3 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Cost of revenue | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 0 | 1 | 0 | 0 |
| Gross profit | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | −1 | 0 | 0 |
| 4 | 4 | 4 | 4 | 3 | 6 | 2 | 2 | 3 | 2 | 3 | 1 | |
| Research & development | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | −1 | 0 | 0 |
| 2 | 4 | 3 | 2 | 2 | 6 | 1 | 1 | 2 | 1 | 2 | 1 | |
| Selling & marketing | 1 | 1 | 1 | 1 | 1 | 3 | 0 | 0 | 1 | 1 | 2 | 1 |
| General & administrative | 1 | 3 | 2 | 1 | 1 | 4 | 1 | 1 | 1 | 1 | 1 | 0 |
| Other expenses | 1 | −1 | 1 | 1 | 1 | −1 | 0 | 0 | 0 | 2 | 0 | 0 |
| Operating income | −2 | −3 | −3 | −2 | −2 | −6 | −2 | −2 | −3 | −3 | −3 | −1 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | −2 | 0 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −1 | 0 | 2 | 0 | 0 |
| Income before tax | −2 | −3 | −3 | −2 | −1 | −6 | −2 | −1 | −3 | −5 | −2 | −1 |
| Net income from continuing operations | −2 | −3 | −3 | −2 | −1 | −6 | −2 | −1 | −3 | −5 | −2 | −1 |
| Net income | −2 | −3 | −3 | −2 | −1 | −6 | −2 | −1 | −3 | −5 | −2 | −1 |
| EPS, basic | −$186.40 | −$270.57 | −$254.22 | −$148.78 | −$83.82 | −$251.11 | −$28.55 | −$16.78 | −$19.05 | −$23.59 | −$6.66 | −$0.98 |
| EPS, diluted | −$186.40 | −$270.57 | −$254.22 | −$148.78 | −$83.82 | −$251.11 | −$28.55 | −$16.78 | −$19.05 | −$23.59 | −$6.66 | −$0.98 |
| Weighted average shares, basic | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Weighted average shares, diluted | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| EBITDA | −2 | −2 | −2 | −1 | −1 | −5 | −1 | −1 | −2 | −5 | −2 | −1 |
| Depreciation & amortization | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −2 | −3 | −3 | −2 | −1 | −6 | −2 | −1 | −3 | −5 | −2 | −1 |
